尹秀芹

[摘要] 目的 探讨分析优泌林联二甲双胍合治疗2型糖尿病临床效果。方法 抽取在该院接受2型糖尿病治疗的100例疾病患者，并将根据患者选择不同的治疗方法将其分组，即研究组（n=50，优泌林+二甲双胍）与对照组（n=50，二甲双胍）。对比两组的治疗疗效、空腹血糖、餐后2 h血糖、糖化血红蛋白、不良反应发生率。结果 研究组的总有效率（96.00%）高于对照组的82.00%，空腹血糖、餐后2 h血糖、糖化血红蛋白均小于对照组，不良反应发生率（4.00%）低于对照组的18.00%，差异有统计学意义（P<0.05）。结论 优泌林联二甲双胍合治疗2型糖尿病具有极高的应用价值，临床效果较佳，安全指数高，该药值得在2型糖尿病的临床治疗中大力推广。

[关键词] 优泌林；二甲双胍；2型糖尿病；安全性

[中图分类号] R587.1 [文献标识码] A [文章编号] 1672-4062（2018）01（a）-0005-02

[Abstract] Objective To study and analyze the clinical effect of humulin combined with melbine in treatment of type 2 diabetes. Methods 100 cases of patients with type 2 diabetes treated in our hospital were selected and divided into two groups with 50 cases in each， the research group were treated with humulin combined with melbine， while the control group were treated with melbine， and the treatment curative effect， fasting blood glucose， postprandial 2 h blood glucose， glycosylated hemoglobin and incidence rate of adverse reactions were compared between the two groups. Results The total effective rate in the research group was higher than that in the control group，the difference was statistically significant（96.00% vs 82.00%）， and the fasting blood glucose， postprandial 2 h blood glucose， and glycosylated hemoglobin were lower than those in the control group， and the incidence rate of adverse reactions was lower than that in the control group （4.00% vs 18.00%）（P<0.05）. Conclusion The application value of humulin combined with melbine in treatment of type 2 diabetes is extremely high， with good clinical effect and high safety index， which is great promotion clinical treatment of type 2 diabetes.

[Key words] Humulin； Melbine； Type 2 diabetes； Safety

2型糖尿病属于一种内分泌疾病，于临床中具有较高的病发率。当人体的血糖值长期处于高水平状态，能够导致大血管、微血管、神经等部位逐渐形成病变，最终导致大脑、肾脏、眼部、心脏等重要器官的功能出现衰退相信，致使各种并并发症的出现率增高[1]。如今，针对2型糖尿病患者的临床治疗，可选择降糖药进行口服，并且在此治疗的基础上添加运动、饮食等护理干预，能够在一定程度上有效控制患者的病情，对其胰岛功能起到较强的改善作用，使得血糖值维持在正常范围内[2]。该文通过探讨分析优泌林联二甲双胍合治疗2型糖尿病临床效果，现报道如下。

1 资料与方法

1.1 一般资料

抽取在该院接受2型糖尿病治疗的100例疾病患者，并将根据患者選择不同的治疗方法将其分组，即研究组（n=50，优泌林+二甲双胍）与对照组（n=50，二甲双胍）。在研究组中，女性患者21例，男性患者29例，年龄在35～85岁之间，平均年龄为（60.26±1.28）岁。……